Amarin (NASDAQ:AMRN - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $45.45 million for the quarter.
Amarin (NASDAQ:AMRN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative return on equity of 17.21%. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Amarin Stock Performance
NASDAQ AMRN traded down $0.11 during trading on Friday, hitting $15.39. 77,769 shares of the company's stock traded hands, compared to its average volume of 93,736. The stock has a market capitalization of $318.73 million, a price-to-earnings ratio of -4.23 and a beta of 0.82. Amarin has a 12-month low of $7.08 and a 12-month high of $17.49. The business has a 50 day moving average of $14.08 and a 200-day moving average of $11.61.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on AMRN. Wall Street Zen raised shares of Amarin from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. The Goldman Sachs Group increased their price target on shares of Amarin from $7.00 to $12.00 and gave the stock a "sell" rating in a report on Wednesday, June 25th.
View Our Latest Report on AMRN
Institutional Investors Weigh In On Amarin
An institutional investor recently raised its position in Amarin stock. Jones Financial Companies Lllp boosted its stake in Amarin Corporation PLC (NASDAQ:AMRN - Free Report) by 449,522.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,811,977 shares of the biopharmaceutical company's stock after purchasing an additional 1,811,574 shares during the quarter. Jones Financial Companies Lllp owned about 8.75% of Amarin worth $815,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 22.25% of the stock is currently owned by institutional investors and hedge funds.
Amarin Company Profile
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access